Literature DB >> 12598709

Seborrheic Keratosis-like lesions in patients with epidermodysplasia verruciformis.

Walmar Roncalli de Oliveira1, Cyro Festa Neto, Peter L Rady, Stephen K Tyring.   

Abstract

Epidermodysplasia verruciformis (EV) is a rare genodermatosis characterized by disseminated infection by human papillomavirus (HPV) and malignant transformation of the lesions in about half of the patients. Two phenotypes of EV have been described according to their propensity to develop malignant tumors. The benign form of EV presents a singular type of lesions comprised of flat warts widely disseminated. The malignant form of EV is highly polymorphic and presents as malignant skin tumors, predominantly basal and squamous cell carcinomas, on sun-exposed sites. The seborrheic keratosis-like (SK) lesions in patients of EV have been reported to be associated with the malignant phenotype. In this work, we documented the behavior of SK-like lesions in nine patients with EV, through clinical observations as well as histological and immunohistochemical findings. We suggest that the HPV infection may promote the occurrence of SK-like lesions in EV patients. Despite the fact that we did not observe any malignant transformation of these lesions in our series of patients, this possibility was not completely excluded.

Entities:  

Mesh:

Year:  2003        PMID: 12598709

Source DB:  PubMed          Journal:  J Dermatol        ISSN: 0385-2407            Impact factor:   4.005


  2 in total

1.  A distinct variant of Epidermodysplasia verruciformis in a Turkish family lacking EVER1 and EVER2 mutations.

Authors:  Baki Akgül; Osman Köse; Mükerrem Safali; Karin Purdie; Rino Cerio; Charlotte Proby; Alan Storey
Journal:  J Dermatol Sci       Date:  2007-02-16       Impact factor: 4.563

2.  No Evidence of Human Papillomaviruses in Non-genital Seborrheic Keratosis.

Authors:  Naser Tayyebi Meibodi; Yalda Nahidi; Zahra Meshkat; Habibollah Esmaili; Masoumeh Gharib; Aida Gholoobi
Journal:  Indian J Dermatol       Date:  2013-07       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.